

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## Amendments to the Specification

1. At page 9 of the application below line 21, please replace the image shown with the following image (one "R<sub>1</sub>" group has been corrected to read "R<sub>2</sub>"):



2. At column 6 line 42, the word "a" following the word "preferably" should be deleted.

As before, R<sub>1</sub> and R<sub>2</sub> are preferably  $\alpha$ -long chain fatty acids between 12 and 24 carbons in length. The variable "n" is preferably an integer between 11 and 46. A number of specific derivatives of the a generic structural configuration of a subset of the group of related lipid molecules of the invention seen in FIG 2 have been synthesized and tested for their ability to inhibit phospholipase A2 and cyclooxygenase-2. Table 2 below lists and describes a number of such derivatives.

## Amendments to the Claims

This listing of claims will replace all prior version, and listings, of claims in the application:

- 1) A lipid compound represented by the formula

